The mechanism of resistance to CDK4/6 inhibition and novel combination therapy with RNR inhibition for chemo-resistant bladder cancer

Zhichao Tong; Yubo Zhao; Shiyu Bai; Benedikt Ebner; Lou Lienhard; Yuling Zhao; Ziqi Wang; Qi Pan; Pengyu Guo; Thilo Bracht; Barbara Sitek; J&uuml;rgen E. Gschwend; Wanhai Xu; Roman Nawroth

doi:10.1002/cac2.12532

Cancer Communications ›› 2024, Vol. 44 ›› Issue (6) : 700-704. DOI: 10.1002/cac2.12532

LETTER TO THE JOURNAL

The mechanism of resistance to CDK4/6 inhibition and novel combination therapy with RNR inhibition for chemo-resistant bladder cancer

Zhichao Tong¹^,²^,³^,⁴ ,
Yubo Zhao¹^,² ,
Shiyu Bai²^,⁴ ,
Benedikt Ebner³^,⁵ ,
Lou Lienhard³ ,
Yuling Zhao³ ,
Ziqi Wang¹^,² ,
Qi Pan³^,⁶ ,
Pengyu Guo¹^,² ,
Thilo Bracht⁷^,⁸ ,
Barbara Sitek⁷^,⁸ ,
Jürgen E. Gschwend³ ,
Wanhai Xu¹^,² ,
Roman Nawroth³

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Zhichao Tong, Yubo Zhao, Shiyu Bai, Benedikt Ebner, Lou Lienhard, Yuling Zhao, Ziqi Wang, Qi Pan, Pengyu Guo, Thilo Bracht, Barbara Sitek, Jürgen E. Gschwend, Wanhai Xu, Roman Nawroth. The mechanism of resistance to CDK4/6 inhibition and novel combination therapy with RNR inhibition for chemo-resistant bladder cancer. Cancer Communications, 2024, 44(6): 700‒704 https://doi.org/10.1002/cac2.12532

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder Cancer: A Review. JAMA. 2020;324(19):1980–1991.

[2]	Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017;171(3):540–556 e25.

[3]	Goel S, Bergholz JS, Zhao JJ. Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer. 2022;22(6):356–372.

[4]	Rubio C, Martinez-Fernandez M, Segovia C, Lodewijk I, Suarez-Cabrera C, Segrelles C, et al. CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status. Clin Cancer Res. 2019;25(1):390–402.

[5]	Rose TL, Chism DD, Alva AS, Deal AM, Maygarden SJ, Whang YE, et al. Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy. Br J Cancer. 2018;119(7):801–807.

[6]	Greene BL, Kang G, Cui C, Bennati M, Nocera DG, Drennan CL, et al. Ribonucleotide Reductases: Structure, Chemistry, and Metabolism Suggest New Therapeutic Targets. Annu Rev Biochem. 2020;89:45–75.

[7]	Zuo Z, Zhou Z, Chang Y, Liu Y, Shen Y, Li Q, et al. Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer. Genes Dis. 2024;11(1):218–233.

[8]	Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, et al. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. Cancer Res. 2016;76(8):2301–2313.

[9]	Zhou B, Su L, Hu S, Hu W, Yip ML, Wu J, et al. A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance. Cancer Res. 2013;73(21):6484–6493.

[10]	Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet. 2016;48(12):1490–1499.